COMMUNIQUÉS West-GlobeNewswire

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
07/08/2025
ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) JELMYTO® [...]
Nualtis Announces Strategic Partnership with OrthoNu for Innovative Orthodontic Care Products
07/08/2025
MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nualtis (formerly IntelGenx Corp.), a leader in oral film drug delivery technologies, today announced a strategic partnership with OrthoNu LLC to develop and manufacture an [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
07/08/2025
Conference Call Scheduled for Friday, August 15, 2025 at 9:00 AM ET PORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company [...]
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
07/08/2025
The final cohort of the single ascending dose (SAD) part of the Phase 1 A VALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025; The multiple ascending dose (MAD) part of the [...]
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
07/08/2025
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will [...]
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
07/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, [...]
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
07/08/2025
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (“ Izotropic ”, or the “ Company ”), a medical device [...]
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
07/08/2025
Topline results from CATT1 Phase 3 trial expected in second half of 2026 HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an [...]
Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL
07/08/2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and [...]
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
07/08/2025
WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial [...]
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
07/08/2025
-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on [...]
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
07/08/2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women’s health between promising science and real solutions, will [...]
Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
07/08/2025
ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global biopharmaceutical company dedicated [...]
Belite Bio Announces Registered Direct Offering of $15 Million
07/08/2025
The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company [...]
Tidewave Bio Reaches Key Regulatory Milestone with FDA INTERACT Meeting Scheduled for August 2025
07/08/2025
Company advances development of first-in-class solid tumor immunotherapy platform LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology company developing a novel immune activation platform for [...]
Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service
07/08/2025
FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, [...]
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
07/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Full Alliance Group's Quant Blockchain Developing HIPAA-Compliant Healthcare Data Sharing Solution
07/08/2025
Strategic Infrastructure Launch Targets $352 Billion Market Ahead of 2027 Regulatory Deadline TAMPA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) announced today that its Qubitera [...]
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
07/08/2025
FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for [...]

Pages